3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Unknown
1
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Bites and Stings
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Gemcitabine
100
130-nm albumin-bound paclitaxel
34
Oxaliplatin
28
Capecitabine
27
Fluorouracil
25
Albumin-Bound Paclitaxel
23
Leucovorin
19
Irinotecan
18
Erlotinib Hydrochloride
14
Cyclophosphamide
12
Radiosurgery
11
pembrolizumab
10
Radiotherapy
10
Nivolumab
10
Bevacizumab
10
Surgical Procedures, Operative
9
avelumab
7
Docetaxel
7
Taxes
6
Cisplatin
6
ruxolitinib
5
folfirinox
5
Specimen Handling
5
Paclitaxel
5
Everolimus
5
Cetuximab
5
ALT-803
5
trametinib
4
spartalizumab
4
fludarabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pancreatic Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05716295
2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2
Terminated
26 enrolled